Radiotherapy developer Actinium Pharmaceuticals is launching ATNM-400, a novel, non-prostate-specific membrane antigen (PSMA) targeting radiotherapy for prostate cancer that uses the actinium-225 (Ac-225) radioisotope.
Initial preclinical data from a study on ATNM-400’s performance will be presented at the American Association for Cancer Research (AACR) annual meeting being held between April 25 and 30 in Chicago. This presentation will share results from in vitro and in vivo studies, including biodistribution imaging and efficacy analyses with various dose levels of ATNM-400.
Actinium is expecting additional data from Pluvicto-resistant prostate cancer models at the AACR meeting. Pluvicto (Lu-177-PSMA-617) is a PSMA-directed targeted radiotherapy that uses the beta-particle emitting radioisotope Lutetitium-177 (Lu-177) that is approved for patients with metastatic prostate cancer. ATNM-400 targets a different marker than PSMA that has been shown to be overexpressed in patients with prostate cancer and uses the alpha-particle emitter Ac-225 which the company said could result in fewer off-target effects.